Eli Lilly commences Covid-19 study with oral JAK1/JAK2 inhibitor baricitinib

Eli Lilly has started Covid-19 study with oral JAK1/JAK2 inhibitor baricitinib. (Credit: Gerd Altmann from Pixabay)